123 related articles for article (PubMed ID: 12399161)
41. Formation and uptake of arylhydroxylamine-haptenated proteins in human dendritic cells.
Roychowdhury S; Vyas PM; Svensson CK
Drug Metab Dispos; 2007 Apr; 35(4):676-81. PubMed ID: 17220235
[TBL] [Abstract][Full Text] [Related]
42. Sulfamethoxazole is metabolized to the hydroxylamine in humans.
Cribb AE; Spielberg SP
Clin Pharmacol Ther; 1992 May; 51(5):522-6. PubMed ID: 1587066
[TBL] [Abstract][Full Text] [Related]
43. Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate.
Masubuchi Y; Igarashi S; Suzuki T; Horie T; Narimatsu S
J Pharmacol Exp Ther; 1996 Nov; 279(2):724-31. PubMed ID: 8930177
[TBL] [Abstract][Full Text] [Related]
44. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
45. Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.
Bhaiya P; Roychowdhury S; Vyas PM; Doll MA; Hein DW; Svensson CK
Toxicol Appl Pharmacol; 2006 Sep; 215(2):158-67. PubMed ID: 16603214
[TBL] [Abstract][Full Text] [Related]
46. Is hydroxylamine-induced cytotoxicity a valid marker for hypersensitivity reactions to sulfamethoxazole in human immunodeficiency virus-infected individuals?
Reilly TP; MacArthur RD; Farrough MJ; Crane LR; Woster PM; Svensson CK
J Pharmacol Exp Ther; 1999 Dec; 291(3):1356-64. PubMed ID: 10565861
[TBL] [Abstract][Full Text] [Related]
47. Improvement of sulfamethoxazole (SMX) elimination and inhibition of formations of hydroxylamine-SMX and N4-acetyl-SMX by membrane bioreactor systems.
Tang MH; Gao N; Zhou J; Zhao Y; Cheng JS; Su WK; Yuan YJ
Biodegradation; 2018 Jun; 29(3):245-258. PubMed ID: 29546497
[TBL] [Abstract][Full Text] [Related]
48. Hepatic disposition of trimethoprim and sulfamethoxazole.
Sahin S; Sayar E; Kaynak MS; Hincal AA
Methods Find Exp Clin Pharmacol; 2008 Mar; 30(2):135-40. PubMed ID: 18560629
[TBL] [Abstract][Full Text] [Related]
49. Direct photolysis of human metabolites of the antibiotic sulfamethoxazole: evidence for abiotic back-transformation.
Bonvin F; Omlin J; Rutler R; Schweizer WB; Alaimo PJ; Strathmann TJ; McNeill K; Kohn T
Environ Sci Technol; 2013 Jul; 47(13):6746-55. PubMed ID: 23186099
[TBL] [Abstract][Full Text] [Related]
50. HIV-1 tat expression and sulphamethoxazole hydroxylamine mediated oxidative stress alter the disulfide proteome in Jurkat T cells.
Adeyanju K; Bend JR; Rieder MJ; Dekaban GA
Virol J; 2018 May; 15(1):82. PubMed ID: 29743079
[TBL] [Abstract][Full Text] [Related]
51. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine.
Gruchalla RS; Sullivan TJ
J Allergy Clin Immunol; 1991 Nov; 88(5):784-92. PubMed ID: 1955637
[TBL] [Abstract][Full Text] [Related]
52. Characterization of Peroxidases Expressed in Human Antigen Presenting Cells and Analysis of the Covalent Binding of Nitroso Sulfamethoxazole to Myeloperoxidase.
Ogese MO; Jenkins RE; Maggs JL; Meng X; Whitaker P; Peckham D; Faulkner L; Park BK; Naisbitt DJ
Chem Res Toxicol; 2015 Jan; 28(1):144-54. PubMed ID: 25531135
[TBL] [Abstract][Full Text] [Related]
53. Nonenzymatic formation of a novel hydroxylated sulfamethoxazole derivative in human liver microsomes: implications for bioanalysis of sulfamethoxazole metabolites.
Sanderson JP; Hollis FJ; Maggs JL; Clarke SE; Naisbitt DJ; Park BK
Drug Metab Dispos; 2008 Dec; 36(12):2424-8. PubMed ID: 18765684
[TBL] [Abstract][Full Text] [Related]
54. Differences in cytochrome P450-mediated biotransformation of 1,2-dichlorobenzene by rat and man: implications for human risk assessment.
Hissink AM; Oudshoorn MJ; Van Ommen B; Haenen GR; Van Bladeren PJ
Chem Res Toxicol; 1996 Dec; 9(8):1249-56. PubMed ID: 8951226
[TBL] [Abstract][Full Text] [Related]
55. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine.
Cribb AE; Spielberg SP
Drug Metab Dispos; 1990; 18(5):784-7. PubMed ID: 1981737
[TBL] [Abstract][Full Text] [Related]
56. Effect of pro-inflammatory cytokines on the toxicity of the arylhydroxylamine metabolites of sulphamethoxazole and dapsone in normal human keratinocytes.
Khan FD; Roychowdhury S; Nemes R; Vyas PM; Woster PM; Svensson CK
Toxicology; 2006 Feb; 218(2-3):90-9. PubMed ID: 16289751
[TBL] [Abstract][Full Text] [Related]
57. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.
Munns AJ; De Voss JJ; Hooper WD; Dickinson RG; Gillam EM
Chem Res Toxicol; 1997 Sep; 10(9):1049-58. PubMed ID: 9305589
[TBL] [Abstract][Full Text] [Related]
58. Urinary biomarkers of trimethoprim bioactivation in vivo following therapeutic dosing in children.
van Haandel L; Goldman JL; Pearce RE; Leeder JS
Chem Res Toxicol; 2014 Feb; 27(2):211-8. PubMed ID: 24380396
[TBL] [Abstract][Full Text] [Related]
59. Interactions between N-acetyl-p-benzoquinone imine and fluorescent calcium probes: implications for mechanistic toxicology.
Riley RJ; Leeder JS; Dosch HM; Spielberg SP
Anal Biochem; 1990 Dec; 191(2):253-61. PubMed ID: 2085171
[TBL] [Abstract][Full Text] [Related]
60. Species and strain differences in the hepatic cytochrome P450-mediated biotransformation of 1,4-dichlorobenzene.
Hissink AM; Oudshoorn MJ; Van Ommen B; Van Bladeren PJ
Toxicol Appl Pharmacol; 1997 Jul; 145(1):1-9. PubMed ID: 9221818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
